Stock Detail
SPECTRUM PHARMACEUTICALS INC
Drug Manufacturers Major
SPPI @ Yahoo Finance | SPPI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $12.50 | $12.74 | $-0.11 | -0.87% | 0.00 | $12.61 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $12.40 | $12.30 | 1.34M | 717.59M | 1.02M | 15.83 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 12.95 | 12.72 | 12.51 | 12.28 | 12.07 |
Stock Profile
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of prescription drug products for the treatment of cancer and related disorders. The company has six drug candidates in clinical development, including Satraplatin for hormone refractory prostate cancer and nonsmall cell lung cancer; EOquin for refractory superficial bladder cancer; Elsamitrucin for refractory nonhodgkin's lymphoma; SPI-153 for hormone dependent prostate cancer and benign prostatic hypertrophy; EO9 for radiation sensitization; RenaZorb for end-stage renal disease and chronic kidney disease; and SPI-1620 for adjunct to chemotherapy. Its Satraplatin product is in phase III clinical trial; EOquin, Elsamitrucin, and SPI-153 products are in phase II clinical trials; and EO9, RenaZorb, and SPI-1620 products are in preclinical trials. The company has strategic alliances with GPC Biotech AG, Johnson Matthey PLC, Bristol-Myers Squibb, Zentaris GmbH, Altair Nanotechnologies, Inc., Chicago Labs, J.B. Chemicals & Pharmaceuticals, Ltd., FDC Limited, and Shantha Biotechnics Pvt., Ltd. The company was incorporated as Americus Funding Corporation in 1987 and changed its name to NeoTherapeutics, Inc. in 1996. NeoTherapeutics changed its name to Spectrum Pharmaceuticals, Inc. in 2002. The company is headquartered in Irvine, California.